Antibody-enzyme conjugates for cancer therapy.

No abstract is available for this paper.

• Publication year

  1996

• Venue

  Journal of the National Cancer Institute

• Publication date

  1996-02-21

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1093/JNCI/88.3-4.153PMID 8632489
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Analysis of a conjugate between anti-carcinoembryonic antigen monoclonal antibody and alkaline phosphatase for specific activation of the prodrug etoposide phosphate

  2005cited by this paper
• Antibody-penicillin-V-amidase conjugates kill antigen-positive tumor cells when combined with doxorubicin phenoxyacetamide

  2005cited by this paper
• Development of a humanized disulfide-stabilized anti-p185HER2 Fv-beta-lactamase fusion protein for activation of a cephalosporin doxorubicin prodrug.

  1995cited by this paper
• Activation and cytotoxicity of 2-alpha-aminoacyl prodrugs of methotrexate.

  1995cited by this paper
• Activation and cytotoxicity of 2-α-aminoacyl prodrugs of methotrexate

  1995cited by this paper
• Methotrexate-alpha-phenylalanine: optimization of methotrexate prodrug for activation by carboxypeptidase A-monoclonal antibody conjugate.

  1995cited by this paper
• Antibody-Catalyzed Prodrug Activation

  1994cited by this paper
• Synthesis of methotrexate prodrugs as an approach for drug targeting.

  1994cited by this paper
• Enhancement of radioimmunotherapy by drugs modifying tumour blood flow in a colonic xenograft model

  1994cited by this paper
• A bifunctional murine::human chimeric antibody with one antigen-binding arm replaced by bacterial beta-lactamase.

  1994cited by this paper
• Tumor-selective prodrug activation by fusion protein-mediated catalysis.

  1994cited by this paper
• Intratumoral generation of 5-fluorouracil mediated by an antibody-cytosine deaminase conjugate in combination with 5-fluorocytosine.

  1994cited by this paper
• Prodrug activation via catalytic antibodies.

  1993cited by this paper
• Tumour necrosis factor increases tumour uptake of co-administered antibody-carboxypeptidase G2 conjugate.

  1993cited by this paper
• Prodrugs of doxorubicin and melphalan and their activation by a monoclonal antibody-penicillin-G amidase conjugate.

  1993cited by this paper
• Genetic construction, expression, and characterization of a single chain anti-carcinoma antibody fused to beta-lactamase.

  1993cited by this paper
• Site-specific prodrug activation by antibody-beta-lactamase conjugates: regression and long-term growth inhibition of human colon carcinoma xenograft models.

  1993cited by this paper
• Antitumor activities of a cephalosporin prodrug in combination with monoclonal antibody-beta-lactamase conjugates.

  1993cited by this paper
• Effect of human immune response on repeat courses of 131-chimeric B72.3 antibody therapy

  1993cited by this paper
• Optimisation of small-scale coupling of A5B7 monoclonal antibody to carboxypeptidase G2.

  1993cited by this paper
• Application of monoclonal antibodies against cytosine deaminase for the in vivo clearance of a cytosine deaminase immunoconjugate.

  1993cited by this paper
• N-(4'-hydroxyphenylacetyl)palytoxin: a palytoxin prodrug that can be activated by a monoclonal antibody-penicillin G amidase conjugate.

  1992cited by this paper
• Activation of methotrexate-alpha-alanine by carboxypeptidase A-monoclonal antibody conjugate.

  1992cited by this paper
• Synthesis of novel targeted pro-prodrugs of anthracyclines potentially activated by a monoclonal antibody galactosidase conjugate (part 1)

  1992cited by this paper
• Molecular and functional characterisation of a fusion protein suited for tumour specific prodrug activation.

  1992cited by this paper
• Two-step strategies for the diagnosis and treatment of cancer with bioconjugates

  1992cited by this paper
• Monoclonal antibody-beta-lactamase conjugates for the activation of a cephalosporin mustard prodrug.

  1992cited by this paper
• Specific activation of glucuronide prodrugs by antibody-targeted enzyme conjugates for cancer therapy.

  1992cited by this paper
• A monoclonal antibody-beta-glucuronidase conjugate as activator of the prodrug epirubicin-glucuronide for specific treatment of cancer.

  1992cited by this paper
• Preparation and characterization of a beta-lactamase-Fab' conjugate for the site-specific activation of oncolytic agents.

  1992cited by this paper
• Antibody Conjugates for the Treatment of Cancer

  1992cited by this paper
• The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)--I. Purification and properties of a nitroreductase enzyme from Escherichia coli--a potential enzyme for antibody-directed enzyme prodrug therapy (ADEPT).

  1992cited by this paper
• The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)--II. A comparison of an Escherichia coli nitroreductase and Walker DT diaphorase.

  1992cited by this paper
• Antibody directed enzyme prodrug therapy (ADEPT): a three phase system.

  1991cited by this paper
• Comparison of half-lives and cytotoxicity of N-chloroethyl-4-amino and N-mesyloxyethyl-benzoyl compounds, products of prodrugs in antibody-directed enzyme prodrug therapy (ADEPT).

  1991cited by this paper
• Antibody directed enzyme prodrug therapy (ADEPT): clinical report.

  1991cited by this paper
• Construction and chemotherapeutic potential of carboxypeptidase-A/monoclonal antibody conjugate.

  1991cited by this paper
• Pharmacokinetic analysis of two-step approaches using bifunctional and enzyme-conjugated antibodies.

  1991cited by this paper
• Carl Prausnitz Memorial Lecture. Suppression of antibody responses by chemically modified antigens.

  1991cited by this paper
• In vitro and in vivo activities of monoclonal antibody-alkaline phosphatase conjugates in combination with phenol mustard phosphate.

  1991cited by this paper
• ANTIBODY-ENZYME CONJUGATES CAN GENERATE CYTOTOXIC DRUGS FROM INACTIVE PRECURSORS AT TUMOR SITES

  1991cited by this paper
• Cephalosporin Nitrogen Mustard Carbamate prodrugs for “ADEPT”.

  1991cited by this paper
• A novel targeted delivery system utilizing a cephalosporin-oncolytic prodrug activated by an antibody β-lactamase conjugate for the treatment of cancer

  1991cited by this paper
• Generation of 5-fluorouracil from 5-fluorocytosine by monoclonal antibody-cytosine deaminase conjugates.

  1991cited by this paper
• Ablation of human choriocarcinoma xenografts in nude mice by antibody-directed enzyme prodrug therapy (ADEPT) with three novel compounds.

  1991cited by this paper
• Anti-neoplastic glucuronide prodrug treatment of human tumor cells targeted with a monoclonal antibody-enzyme conjugate.

  1991cited by this paper
• Novel prodrugs which are activated to cytotoxic alkylating agents by carboxypeptidase G2.

  1990cited by this paper
• Activation of prodrugs by antibody‐enzyme conjugates: a new approach to cancer therapy

  1990cited by this paper
• Specific activation of the prodrug mitomycin phosphate by a bispecific anti-CD30/anti-alkaline phosphatase monoclonal antibody.

  1990cited by this paper
• Inactivation and clearance of an anti-CEA carboxypeptidase G2 conjugate in blood after localisation in a xenograft model.

  1990cited by this paper
• Enhancement of the in vitro and in vivo antitumor activities of phosphorylated mitomycin C and etoposide derivatives by monoclonal antibody-alkaline phosphatase conjugates.

  1989cited by this paper
• Selective Cytotoxicity of Carboxypeptidase-activated Methotrexate ex-Peptides

  1989cited by this paper
• Carboxypeptidase-mediated release of methotrexate from methotrexate alpha-peptides.

  1989cited by this paper
• The First Bagshawe lecture. Towards generating cytotoxic agents at cancer sites.

  1989cited by this paper
• Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans.

  1988cited by this paper
• A cytotoxic agent can be generated selectively at cancer sites.

  1988cited by this paper
• Preclinical studies and clinical correlation of the effect of alkylating dose.

  1988cited by this paper
• Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate.

  1988cited by this paper
• Sequence and comparative analysis of three Enterobacter cloacae ampC beta-lactamase genes and their products.

  1988cited by this paper
• The nitroreductase enzyme in Walker cells that activates 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) to 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide is a form of NAD(P)H dehydrogenase (quinone) (EC 1.6.99.2).

  1988cited by this paper
• Antibody directed enzymes revive anti-cancer prodrugs concept.

  1987cited by this paper
• The diffusion of a tumour-specific monoclonal antibody in lymphoma infiltrated spleen.

  1987cited by this paper
• The effect of tumor CEA content and tumor size on tissue uptake of indium 111‐labeled anti‐CEA monoclonal antibody

  1986cited by this paper
• Improvement of Tumor Cell Detection Using a Pool of Monoclonal Antibodies

  1986cited by this paper
• Heterogeneity of cell surface antigen expression of human small cell lung cancer detected by monoclonal antibodies.

  1986cited by this paper
• The complete nucleotide sequence of the Pseudomonas gene coding for carboxypeptidase G2.

  1984cited by this paper
• Recombinant antibodies possessing novel effector functions

  1984cited by this paper
• Definition of antigenic heterogeneity and modulation among human mammary carcinoma cell populations using monoclonal antibodies to tumor-associated antigens.

  1983cited by this paper
• The action of palytoxin on erythrocytes and resealed ghosts

  1983cited by this paper
• Antigenic heterogeneity of surgically removed primary and autologous metastatic human melanoma lesions.

  1983cited by this paper
• Cellular distribution of monoclonal antibody in human tumours after i.v. administration.

  1981cited by this paper
• The clinical pharmacology of methotrexate. new applications of an old drug

  1978cited by this paper
• Antibody to a molecularly-defined antigen confined to a tumour cell surface

  1975cited by this paper
• Metabolism of aniline mustard (N,N-di-(2-chloroethyl)aniline).

  1973cited by this paper
• Evaluation of aniline mustard in patients with multiple myeloma.

  1973cited by this paper
• Palytoxin: A New Marine Toxin from a Coelenterate

  1971cited by this paper
• Cure of Mice bearing Advanced Plasma Cell Tumours with Aniline Mustard : the Relationship between Glucuronidase Activity and Tumour Sensitivity

  1966cited by this paper

• Expanding horizons in cancer therapy by immunoconjugates targeting tumor microenvironments.

  2024cites this paper
• Extracellular targeted protein degradation: an emerging modality for drug discovery

  2023cites this paper
• Bringing enzymes to the proximity party

  2023cites this paper
• Anti-PD-L1 immunoconjugates for cancer therapy: Are available antibodies good carriers for toxic payload delivering?

  2022cites this paper
• “One stroke drawing” of poly(ribonucleic acids) with different aptamer functions for sensing probes

  2021cites this paper
• Unlocking the therapeutic potential of artificial metalloenzymes

  2020cites this paper
• Synthetic Tuning of Domain Stoichiometry in Nanobody-Enzyme Megamolecules.

  2020cites this paper
• Highly Bactericidal Silver () against Bacteria and Anti-Cancer Activity of Ag+ ions for Regulation of Cancer/Tumor Cell Growth

  2018cites this paper
• SKIK-zipbody-alkaline phosphatase, a novel antibody fusion protein expressed in Escherichia coli cytoplasm.

  2018cites this paper
• Zipbodyzyme: Development of new antibody-enzyme fusion proteins.

  2018cites this paper
• Monoclonal antibodies in the detection and treatment of micrometastatic or minimal residual disease; an overview

  2018cites this paper
• Availability of Ag+ Ions Having Most Highly Bactericidal Activity to Suppression by Inhibitions of Viral and Cancerous Cell Growth

  2018cites this paper
• Engineering carboxypeptidase G2 circular permutations for the design of an autoinhibited enzyme

  2017cites this paper
• Synergistic photodynamic therapeutic effect of indole-3-acetic acid using a pH sensitive nano-carrier based on poly(aspartic acid-graft-imidazole)-poly(ethylene glycol).

  2017cites this paper
• A Comprehensive Review on Function and Application of PlantPeroxidases

  2017cites this paper
• Strategies in the designing of prodrugs, taking into account the antiviral and anticancer compounds.

  2017cites this paper
• Immunotherapy against cancer: A comprehensive review

  2016cites this paper
• A Review on Immunotherapy against Cancer

  2016cites this paper
• Glyco-engineered horseradish peroxidase for targeted cancer treatment

  2015cites this paper
• ANTIBACTERIAL PREDRUGS-FROM 1899 TILL 2015

  2015cites this paper
• Ligand-Appended BBB-Targeted Nanocarriers (LABTNs).

  2015cites this paper
• Anti-cancer Prodrugs-Three Decades of Design

  2015cites this paper
• Development of Lipid Based Nanoparticulate Drug Delivery Systems and Drug Carrier Complexes for Delivery to Brain

  2015cites this paper
• Using predrugs to optimize drug candidates

  2014cites this paper
• Proteases as activators for cytotoxic prodrugs in antitumor therapy.

  2014cites this paper
• Human β-Glucuronidase: Structure, Function, and Application in Enzyme Replacement Therapy

  2013cites this paper
• Chapter 355 – Glutamate Carboxypeptidase

  2013cites this paper
• Oral delivery of an anti-diabetic peptide drug via conjugation and complexation with low molecular weight chitosan.

  2013cites this paper
• Production and purification of the multifunctional enzyme horseradish peroxidase.

  2013cites this paper
• CEACAM1 is a Privileged Cell Surface Antigen to Design Novel ScFv Mediated-Immunotherapies of Melanoma, Lung Cancer and Other Typesof Tumors

  2012cites this paper
• Synthesis, characterization, and antitumor activity of rare earth metal complexes of benzoic acid nitrogen mustard

  2012cites this paper
• Monoclonal antibodies for the immunotherapy of solid tumours.

  2012cites this paper
• Antibody-targeted horseradish peroxidase associated with indole-3-acetic acid induces apoptosis in vitro in hematological malignancies.

  2011cites this paper
• Prodrugs for improving tumor targetability and efficiency.

  2011cites this paper
• Rekombinante Antikörper-Enzym-Fusionskonstrukte zur zielgerichteten Therapie kolorektaler Karzinome

  2010cites this paper
• A novel approach to oral delivery of insulin by conjugating with low molecular weight chitosan.

  2010cites this paper
• Strategy for effective brain drug delivery.

  2010cites this paper
• Potential approaches for drug delivery to the brain: past, present, and future.

  2010cites this paper
• Design and synthesis of novel N10 protected pyrrolobenzodiazepines for use in ADEPT and GDEPT

  2009cites this paper
• Developing bifunctional β‐lactamase molecules with built‐in target‐recognizing module for prodrug therapy: identification of Enterobacter Cloacae P99 cephalosporinase loops suitable for randomization and phage‐display selection

  2009cites this paper
• Oral delivery of protein-transporter bioconjugates using intelligent complexation hydrogels

  2008influential citation
• Prodrugs in cancer chemotherapy

  2008cites this paper
• Catalytic activity of certain antibodies as a potential tool for drug synthesis and for directed prodrug therapies.

  2008cites this paper
• The extracellular regions of PSMA and the transferrin receptor contain an aminopeptidase domain: Implications for drug design

  2008cites this paper
• Improved biochemical strategies for targeted delivery of taxoids.

  2007cites this paper
• Molecular-docking-guided design, synthesis, and biologic evaluation of radioiodinated quinazolinone prodrugs.

  2007cites this paper
• The design and synthesis of duocarmycin prodrugs

  2006cites this paper
• In silico design, synthesis, and biological evaluation of radioiodinated quinazolinone derivatives for alkaline phosphatase–mediated cancer diagnosis and therapy

  2006cites this paper
• Synthesis and characterization of insulin-transferrin conjugates.

  2006cites this paper
• In vitro and in vivo behavior of insulin delivery systems based on poly(ethylene glycol)-grafted poly(methacrylic acid) hydrogels

  2005cites this paper
• Bacterial Systems for Tumor-Specific Gene Therapy

  2005cites this paper
• Targeted protein functionalization using His-tags.

  2004cites this paper
• 282 – Glutamate carboxypeptidase

  2004cites this paper
• Antibody Fragments: Production, purification and formatting for therapeutic applications

  2004cites this paper
• Monoclonal antibodies in cancer therapy

  2004cites this paper
• Selective activation of anthracycline prodrugs for use in conjunction with ADEPT.

  2003cites this paper
• Conditionally cleavable radioimmunoconjugates: a novel approach for the release of radioisotopes from radioimmunoconjugates.

  2003cites this paper
• Horseradish peroxidase: a valuable tool in biotechnology.

  2003cites this paper
• Enzyme/abzyme prodrug activation systems: potential use in clinical oncology.

  2003cites this paper
• Mechanisms of cytotoxicity induced by horseradish peroxidase/indole‐3‐acetic acid gene therapy

  2002cites this paper
• Synthesis and biologic evaluation of a radioiodinated quinazolinone derivative for enzyme-mediated insolubilization therapy.

  2002cites this paper
• Bacterial protease inhibitors

  2002cites this paper
• Critical appraisals of approaches for predictive designs in anticancer drugs

  2002cites this paper
• Alternative splicing as a novel of means of regulating the expression of therapeutic genes

  2002cites this paper
• CHAPTER 8 – GENE-DIRECTED ENZYME PRODRUG THERAPY

  2002cites this paper
• Prodrug and antedrug: Two diametrical approaches in designing safer drugs

  2002cites this paper
• Crystal structure of a bacterial cocaine esterase

  2002cites this paper
• Aerobic nitroreduction by flavoproteins: enzyme structure, mechanisms and role in cancer chemotherapy.

  2001cites this paper
• Bacterial proteases: current therapeutic use and future prospects for the development of new antibiotics

  2001cites this paper
• Medicinals for the millennia: the historical record.

  2001cites this paper
• Oxidative activation of indole-3-acetic acids to cytotoxic species- a potential new role for plant auxins in cancer therapy.

  2001cites this paper
• Medicinals for the Millennia

  2001cites this paper
• The Historical Record

  2001cites this paper
• Horseradish peroxidase-mediated gene therapy: choice of prodrugs in oxic and anoxic tumor conditions.

  2001cites this paper
• Pharmacokinetics and microdistribution of polyethylene glycol‐modified humanized A33 antibody targeting colon cancer xenografts

  2000cites this paper
• Development and validation of a mathematical model to describe anti-cancer prodrug activation by antibody-Enzyme conjugates

  2000cites this paper
• Approaches to New Drug Discovery

  2000cites this paper
• [Targeting of antitumor drugs with monoclonal antibodies].

  2000cites this paper
• Antineoplastic agents from natural sources: achievements and future directions

  2000cites this paper
• Design, Synthesis and Evaluation of Imidazolylmethyl Carbamate Prodrugs of Alkylating Agents.

  2000cites this paper
• Prodrugs of natural anthracycleves suited for antibody directed enzyme prodrug therapy (ADEPT) and prodrug monotherapy (PMT)

  2000cites this paper
• Leaving group effects in reductively triggered fragmentation of 4-nitrobenzyl carbamates

  2000cites this paper
• Potential use of radiolabeled glucuronide prodrugs with auger and/or alpha emitters in combined chemo- and radio-therapy of cancer.

  2000cites this paper
• Recent strategies in the development of taxane anticancer drugs

  2000cites this paper
• Novel inhibitors of carboxypeptidase G2 (CPG2): potential use in antibody-directed enzyme prodrug therapy.

  1999cites this paper
• A 2-nitroimidazole carbamate prodrug of 5-amimo-1-(chloromethyl)-3-[(5,6,7-trimethoxyindol-2-yl)carbony l]-1,2-dihydro-3H--benz[E]indole (amino-seco-CBI-TMI) for use with ADEPT and GDEPT.

  1999cites this paper
• Suppression of solid tumor growth by a monoclonal antibody against tumor vasculature in rats: Involvement of intravascular thrombosis and fibrinogenesis

  1999cites this paper
• Discovery and development of antineoplastic agents from natural sources.

  1999cites this paper
• Prodrugs for antibody- and gene-directed enzyme prodrug therapies (ADEPT and GDEPT).

  1999cites this paper
• Folate-targeted enzyme prodrug cancer therapy utilizing penicillin-V amidase and a doxorubicin prodrug.

  1999cites this paper
• Theoretical analysis of conjugate localization in two-step cancer chemotherapy

  1999cites this paper
• Natural Product Drug Discovery and Development

  1999cites this paper
• Factors Influencing Tumor-Selective Localization of Antibody Conjugates

  1999cites this paper
• Discovery and Development of Antineoplastic Agents from Natural Sources

  1999cites this paper
• Comparison of recombinant and synthetically formed monoclonal antibody-beta-lactamase conjugates for anticancer prodrug activation.

  1999cites this paper
• Mathematical and experimental analysis of localization of anti-tumour antibody–enzyme conjugates

  1999influential citation
• Immunoconjugates as Anti-Cancer Agents

  1998cites this paper
• Prodrugs of anthracyclines for use in antibody-directed enzyme prodrug therapy.

  1998cites this paper
• Tumor efficacy and bone marrow-sparing properties of TER286, a cytotoxin activated by glutathione S-transferase.

  1998cites this paper
• New developments in the use of nitrogen mustard alkylating agents as anticancer drugs

  1998cites this paper